Sign in

    Kevin Ali

    Chief Executive Officer (CEO) at Organon & Co
    Since 2021
    Age
    63 years
    Education
    Holds an M.B.A. from Santa Clara University and a bachelor's degree from the University of California, Berkeley.
    Tenure
    Joined OGN in 2021 as the Chief Executive Officer, leading the company from its inception.

    Also at Organon & Co

    KW
    Kirke Weaver
    EVP, General Counsel, and Corporate Secretary
    MW
    Matthew Walsh
    Executive Vice President and CFO

    About

    Kevin Ali is a seasoned leader in the pharmaceutical industry with over three decades of experience in healthcare commercialization and strategic management. He began his notable career at Merck & Co., Inc., where he held progressive roles including Managing Director in Turkey and Germany, Senior Vice President in various capacity, as well as leading the Emerging Markets and International Business divisions. His leadership in these diverse roles laid the groundwork for his future contributions to the healthcare sector.

    In 2021, he took on the role of Chief Executive Officer at OGN, a company founded with a mission to improve women's health globally. His vision and strategic approach have been instrumental in shaping the company from its inception, where he was key in designing the organizational structure and selecting the senior leadership team.

    Beyond his executive responsibilities, his professional journey reflects a commitment to innovative approaches in global healthcare markets. His extensive background from his days at Merck to his current role underscores the integration of international experience with a focus on transformative healthcare solutions.

    $OGN Performance Under Kevin Ali

    Past Roles

    OrganizationRoleDate RangeDetails
    Merck & Co., Inc.President, Global Enterprise Portfolio Strategy2019-2021Led global enterprise portfolio strategy initiative contributing to Organon formation
    Merck & Co., Inc. - MSD InternationalPresident, Merck Sharp & Dohme Corp. (MSD) International2017-2019Responsible for commercial markets outside the U.S., covering 96% of world population and over half of Merck’s pharmaceutical revenues
    Merck & Co., Inc.President, Emerging Markets2010-2017Transformed performance in various countries for sustained growth and strength
    Merck & Co., Inc.Senior Vice President and General Manager, Bone, Respiratory, Immunology and Dermatology Franchise2009-2011Led key therapeutic franchises
    Merck & Co., Inc. - MSD GermanySenior Vice President and Managing Director2005-2010Managed operations in Germany
    Merck & Co., Inc. - MSD TurkeyManaging Director2003-2005Managed operations in Turkey

    Fixed Compensation

    Data from  FY 2023
    Component NameAmount ($)Payment ScheduleAdditional Details
    Base Salary1,250,000 AnnualFixed annual salary.
    401(k) Plan Company Contributions14,850 AnnualContributions to the 401(k) plan.
    U.S. Non-Qualified Savings Plan432,001 AnnualContributions exceeding IRS limits for the 401(k) plan.
    Relocation Expenses168,882 One-timeIncludes Housing: 107,751; Tax compliance services: 54,509; Miscellaneous: 6,623.
    Tax Gross-Up4,241 One-timeLegacy tax equalization payments from Merck related to equity awards issued in and prior to 2020.
    Security Services120,549 AnnualIncludes Personal driver and vehicle: 106,850; Residential monitoring: 13,700.

    Performance Compensation

    Data from  FY 2023

    Annual Incentive Plan (AIP)

    MetricDetail/Value
    Performance Metrics40% Revenue, 40% Adjusted EBITDA, 20% Organizational Health Priorities
    ThresholdMinimum performance level (not explicitly quantified)
    Target$1,875,000 (150% of base salary)
    Maximum$3,750,000 (200% of the target)
    Actual Scorecard Result98% resulting in a final award of $1,837,500
    Evaluation Period2023
    VestingNo vesting; cash-based payout

    Performance Stock Units (PSUs)

    MetricDetail/Value
    Performance Metrics70% Three-Year Cumulative Free Cash Flow, 30% Relative TSR
    Threshold Payout50% payout at the 25th percentile
    Target Payout100% payout at the 55th percentile
    Maximum Payout200% payout at the 75th percentile
    Grant DateMarch 31, 2023
    Grant Date Fair Value$5,510,668
    Grant Date Stock Price$23.52 per share
    Units GrantedThreshold: 118,790; Target: 237,580; Maximum: 475,160
    Vesting ScheduleVest on December 31, 2025 upon achievement of performance conditions
    Evaluation PeriodJanuary 1, 2023 – December 31, 2025

    Equity Incentive Plan Awards

    ComponentDetail/Value
    Components IncludedPSUs, Restricted Stock Units (RSUs), and Non-Qualified Stock Options (NQSOs)
    RSUs Units Granted116,921
    RSUs VestingVest in three equal annual installments on each anniversary of the grant date
    NQSOs Units Granted419,847
    NQSOs Exercise Price$23.52 per share
    NQSOs VestingVest in three equal annual installments on each anniversary of the grant date
    Grant Date for All AwardsMarch 31, 2023
    RSUs Grant Fair Value$2,749,982
    NQSOs Grant Fair Value$2,749,368
    PSUs Performance ConditionsAchievement of FCF and Relative TSR goals over the period January 1, 2023 – December 31, 2025

    This detailed structure aligns the performance compensation components with the company’s strategic financial goals and performance indicators.